<DOC>
	<DOC>NCT01709929</DOC>
	<brief_summary>This trial is conducted in North America. The aim of this trial is to evaluate the safety of insulin detemir for the treatment of diabetes.</brief_summary>
	<brief_title>Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Diagnosed with type 1 or type 2 diabetes Using a basal/bolus insulin regimen Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit Subjects who previously enrolled in this study Subjects with a hypersensitivity to insulin detemir or to any of the excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>